Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Candel Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +2 vs. Q2 2022
- Shares held
- 6.08M
- −264.9K (−4.2%) vs. Q2 2022
- Total value
- $19.1M
- −$1.46M (−7.1%) vs. Q2 2022
- New holders
- 4
- 7 more added
- Sold out
- 2
- 3 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CADL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 137 | $518.9M |
| Q1 2026 | 114 | $212.9M |
| Q4 2025 | 84 | $133.5M |
| Q3 2025 | 81 | $115.6M |
| Q2 2025 | 78 | $116.6M |
| Q1 2025 | 82 | $119.7M |
| Q4 2024 | 71 | $155.7M |
| Q3 2024 | 52 | $46.4M |
| Q2 2024 | 45 | $37.0M |
| Q1 2024 | 20 | $5.97M |
| Q4 2023 | 22 | $5.92M |
| Q3 2023 | 20 | $4.86M |
| Q2 2023 | 20 | $6.77M |
| Q1 2023 | 21 | $7.44M |
| Q4 2022 | 21 | $9.70M |
| Q3 2022 | 25 | $19.1M |
| Q2 2022 | 23 | $20.6M |
| Q1 2022 | 23 | $34.0M |
| Q4 2021 | 20 | $54.4M |
| Q3 2021 | 12 | $52.9M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Candel Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Northpond Ventures, LLC | 1,935,215 | $6.08M | 4.26% | 00.0% | Unchanged |
| Franklin Resources Inc | 1,125,000 | $3.53M | 0.00% | 00.0% | Unchanged |
| FMR LLC | 899,399 | $2.82M | 0.00% | 00.0% | Unchanged |
| Sands Capital Ventures, LLC | 811,737 | $2.55M | 0.74% | 00.0% | Unchanged |
| Vanguard Group Inc | 405,461 | $1.27M | 0.00% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 403,131 | $1.27M | 0.01% | −339,951−45.7% | Reduced |
| Bridgeway Capital Management, LLC | 132,700 | $417.0K | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 128,846 | $404.0K | 0.00% | +53,629+71.3% | Added |
| BlackRock Inc. | 124,970 | $393.0K | 0.00% | −4,407−3.4% | Reduced |
| State Street Corp | 27,600 | $87.0K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 16,851 | $53.0K | 0.00% | +16,851 | New |
| Millennium Management LLC | 14,844 | $47.0K | 0.00% | +14,844 | New |
| Northern Trust Corp | 14,483 | $45.0K | 0.00% | 00.0% | Unchanged |
| Kestra Advisory Services, LLC | 12,500 | $39.0K | 0.00% | 00.0% | Unchanged |
| Empirical Asset Management, LLC | 12,000 | $38.0K | 0.04% | 00.0% | Unchanged |
| Morgan Stanley | 5,280 | $17.0K | 0.00% | +659+14.3% | Added |
| UBS Group AG | 4,181 | $13.0K | 0.00% | +374+9.8% | Added |
| Tower Research Capital LLC (TRC) | 4,137 | $13.0K | 0.00% | +2,918+239.4% | Added |
| JPMorgan Chase & Co | 1,458 | $5.00K | 0.00% | +211+16.9% | Added |
| BNP Paribas Arbitrage, SA | 410 | $1.29K | 0.00% | +410 | New |
| Citigroup Inc | 335 | $1.00K | 0.00% | −95−22.1% | Reduced |
| Quent Capital, LLC | 182 | $1.00K | 0.00% | 00.0% | Unchanged |
| China Universal Asset Management Co., Ltd. | 271 | $1.00K | 0.00% | +271 | New |
| Bank of America Corp | 206 | $0 | 0.00% | +56+37.3% | Added |
| Wells Fargo & Company | 96 | $0 | 0.00% | +35+57.4% | Added |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −10,037−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −640−100.0% | Sold out |